Updated on 19 October 2026
Disrupting Gram Negative bacterial biofilms
Chief Scientific Officer at Biophys Limited
Cardiff, United Kingdom
About
We would like to partner with developers of novel antimicrobial agents against priority Gram-negative bacteria to develop co-therapies that can be administered orally, by IV or IP.
We are a small organisation and cannot lead such a project, but we can provide small-molecule scaffolds and conduct antibiofilm and cytotoxicity research in our own BSL Class 2 facilities.
Topic
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Organisation
Similar opportunities
Project cooperation
New Generation Switchable Living Drugs
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Ilaria PITTON
Research Facilitator at Ca'Foscari University of Venice
Venice, Italy
Project cooperation
RNA structure and viral genomics partner for antiviral discovery
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Michael Wolfinger
Founder & Principal Scientist, RNA Forecast e.U. at RNA Forecast e.U.
Vienna, Austria
Project cooperation
Implementation Intelligence for Product Development and Market Introduction
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
Reda Sadki
Executive director at The Geneva Learning Foundation
Geneva, Switzerland